X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Asia

Hitachi Medical Systems Europe Introduces “LISENDO 880”, th New Premium 2D/4D CARDIOVASCULAR Ultrasound System

Yuvraj_pawp by Yuvraj_pawp
6th December 2017
in Asia, News

Premium cardiac and vascular imaging rises to a new standard as Hitachi Medical Systems Europe introduces its new premium 2D/4D cardiovascular ultrasound system, the LISENDO 880, featuring HDAnalyticsTM, a unique and accurate cardiovascular analysis package for confident cardiac hemodynamic assessments, at EuroEcho Imaging 2017 in Lisbon, Portugal, December 6, 2017.

Since their inception, today’s ultrasound systems have progressed to become essential medical devices for all levels of cardiovascular care. The LISENDO 880 is Hitachi’s new premium 2D/4D diagnostic ultrasound solution for cardiologists that redefines the vision of cardiac ultrasound by providing exceptional clinical performance coupled with state-of-the-art features and analytics.

Hitachi released the world’s first diagnostic ultrasound system in 1960 and the world’s first Colour Doppler ultrasound system in 1983. Continuing this history of innovation, Hitachi introduced Vector Flow Mapping (VFM) analysis using ultrasound in 2013. Hitachi stands out as a company dedicated to providing unique solutions to echocardiography’s clinical challenges. The LISENDO 880 maintains Hitachi’s tradition of providing exceptionally innovative ultrasound for cardiovascular care.

The LISENDO 880 was developed to address the most important needs for cardiovascular imaging:

Pure Image Technology
The advanced architecture of the LISENDO 880 offers state-of-the-art transducer technology for 2D/4D imaging, a high performance OLED display, premium image optimization parameters such as eFocusing and Pure Symphonic Architecture to capture the subtlest of changes and produce the highest-quality ‘sound’.

Seamless Workflow
The LISENDO 880 was designed to provide maximum scanning comfort, along with state-of-the-art technology to help you complete your exams more easily. LISENDO’s flexible positioning which includes a four-point articulating monitor arm and adjustable panel height, supports comfortable operation while the operation panel allows ergonomic function adjustment as a part of our intuitive user interface. LISENDO 880 delivers seamless workflow users expect in a premium ultrasound system.

Additionally, LISENDO 880 is equipped with a sophisticated automatic anatomy recognition and cardiac function measurement package based on our HDSI (HemoDynamic Structural Intelligence). Smart cardiac measurements, using learning data structured by Hitachi’s big data and Artificial Intelligence (AI) technology significantly improve the examination efficiency and create new value with Hitachi’s unique solutions.

Your Application
The LISENDO 880 is Hitachi’s most advanced ultrasound system offering premium 2D/4D cardiovascular applications and innovative cardiac imaging features, namely the unique HDAnalyticsâ„¢ (HemoDynamic Analytics) package which includes LVeFlow, iDGD (Dual Gate Doppler) with R-R Navigation, VFM (Vector Flow Mapping) and eTRACKING with Wave Intensity. In addition, LISENDO 880 offers the Eyeball EF and i2DTT quantification tools.

With these features, LISENDO 880 moves cardiac evaluations to a new level and maintains Hitachi’s tradition of providing exceptionally innovative ultrasound for cardiovascular care.

About Hitachi Medical Systems Europe
Hitachi Healthcare in Europe is represented by Hitachi Medical Systems Europe Holding AG, Zug, Switzerland. The company is a first choice supplier of open and powerful high-field MRI systems, multi-slice CT systems as well as medical ultrasound, endoscopic and optical topography systems (NIRS). Ultrasound expertise encompasses clinical applications such as cardiology, radiology, internal medicine, obstetrics/gynecology, gastroenterology, urology and surgery. Hitachi Medical Systems Europe offers a complete range of solutions to address a wide range of medical challenges. For more information about Hitachi Medical Systems Europe Holding AG,

For more information, please visit http://www.hitachi-medical-systems.eu

About Hitachi, Ltd.
Hitachi, Ltd. (TSE: 6501), headquartered in Tokyo, Japan, delivers innovations that answer society’s challenges. The company’s consolidated revenues for fiscal 2016 (ended March 31, 2017) totaled 9,162.2 billion yen ($81.8 billion). The Hitachi Group is a global leader in the Social Innovation Business, and it has approximately 304,000 employees worldwide. Through collaborative creation, Hitachi is providing solutions to customers in a broad range of sectors, including Power / Energy, Industry / Distribution / Water, Urban Development, and Finance / Government & Public / Healthcare. For more information on Hitachi, please visit the company’s website at http://www.hitachi.com

Contact:
Romea Wallnoefer
Hitachi Medical Systems Europe Holding AG
r.wallnoefer@hitachi-medical-systems.com
+41-41-748-63-33

Previous Post

Canon BioMedical products now available in Austria, Germany, and Switzerland

Next Post

Johnson & Johnson Announces Development Of Zika Vaccine

Related Posts

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
GSK commences phase III study of Benlysta and rituximab combination in systemic lupus erythematosus
Manufacturing

GSK Commits £1 Billion To Combat Infections In Poor Nations

27th June 2022
Next Post

Johnson & Johnson Announces Development Of Zika Vaccine

Latest News

FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis To Slash 8,000 Jobs To Save $1 Billion By 2024

30th June 2022
How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace
Manufacturing

How Lag In African COVID-19 Jabs Slowed Its Once Rapid Pace

27th June 2022
Australia Creates A Novel Stem Cell Production Technique
Manufacturing

Australia Creates A Novel Stem Cell Production Technique

27th June 2022
Novartis to acquire The Medicines Company for USD 9.7 bn
Manufacturing

Novartis Promises $250M For Tropical Illnesses, Malaria

27th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In